GlaxoSmithKline CEO Sees Limited Impact From Cervarix Delay

LONDON, Oct 26 (Reuters) - GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research) said on Thursday a delay in filing its cervical cancer vaccine Cervarix for approval in the United States would have little impact on the product’s market potential.

>>> Discuss This Story